Cyramza (Ramucirumab)
- Medicine Name: Cyramza
- Generic Name: Ramucirumab
- Dosage Form & Strength: Injection: 100 mg/10 mL (10 mg/mL) or 500 mg/50 mL (10 mg/mL) solution in a single-dose vial
- Manufactured By: Eli Lilly and Company
Medical Uses
Cyramza is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist used:
- as a single agent or together with paclitaxel, to treat advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or following prior fluoropyrimidine- or platinum-containing chemotherapy.
- together with erlotinib, for first-line treatment of metastatic NSCLC with EGFR exon-19 deletions or exon-21 (L858R) mutations.
- together with docetaxel, to treat metastatic NSCLC with disease progression on or after platinum-based chemotherapy.
- together with Folfiri, to treat metastatic colorectal cancer with disease progression on or after prior therapy with oxaliplatin, bevacizumab, and a fluoropyrimidine.
- as a single agent, to treat hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with medicine sorafenib.
Recommended Dosage: The cyramza injection is for intravenous infusion only. It is not for use as an intravenous push or bolus. Premedicate prior to each infusion.
Gastric Cancer: The recommended dosage, either as a single agent or together with weekly paclitaxel, is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes. In case the first infusion is tolerated, all subsequent infusions of cyramza may be administered over 30 minutes. Continue treatment until the disease is progressive or unacceptable toxicity occurs. When given together with paclitaxel, administer Cyramza before the administration of paclitaxel.
Non-Small Cell Lung Cancer: The recommended dosage for NSCLC in Combination with Erlotinib is 10 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes. In case the first infusion is tolerated, all the subsequent cyramza infusions may be administered over 30 minutes. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
The recommended dosage for NSCLC in Combination with drug Docetaxel is 10 mg/kg administered by intravenous infusion over 60 minutes on Day 1 of a 21-day cycle prior to the infusion of docetaxel. In case the first infusion is tolerated, all the subsequent infusions of Cyramza may be administered over 30 minutes. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Colorectal Cancer: The recommended dosage is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes before the administration of Folfiri. In case the first infusion is tolerated, all the subsequent infusions may be administered over 30 minutes. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Hepatocellular Carcinoma: The recommended dosage is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes. In case the first infusion is tolerated, all subsequent infusions may be administered over 30 minutes. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Warning & Precautions
- Prior to each infusion of Cyramza 100 mg, all the patients should be premeditated with an intravenous histamine-1 receptor antagonist (e.g., diphenhydramine hydrochloride).
- For those patients who have experienced a Grade 1/2 IRR, premedicate with a histamine-1 receptor antagonist, dexamethasone (or equivalent), and acetaminophen before the each infusion.
- Ramucirumab increases the probability of hemorrhage and gastrointestinal hemorrhage, including fatal and severe events. Permanently discontinue ramucirumab 500 mg injection in patients who experience severe bleeding.
- Ramucirumab increases the probability of gastrointestinal perforation, which may be fatal. Permanently discontinue this drug in patients who experience a gastrointestinal perforation.
- Withhold Ramucirumab for 28 days before the elective surgery. Avoid administering this drug for at least 14 days after a major surgical procedure and until adequate wound healing.
- Severe and sometimes fatal ATEs (arterial thromboembolic events) can occur with ramucirumab 100 mg injection. Permanently discontinue the injection in patients who experience an ATE.
- Monitor blood pressure and treat hypertension. Withhold Ramucirumab for severe hypertension. Permanently discontinue it for hypertension that cannot be managed with antihypertensive therapy and for hypertensive crisis or hypertensive encephalopathy.
- Monitor for signs/symptoms of infusion-related reactions (IRR) during infusion. Reduce the infusion rate for Grade 1/2 IRR and permanently interrupt for Grade 3/4 IRR.
- Monitor for proteinuria. Withhold Cyramza 500 mg injection for urine protein levels higher than or equal to 2g/24 hours. Permanently discontinue treatment for urine protein levels higher than 3g/24 hours or nephrotic syndrome.
- Treatment with ramucirumab can be responsible for causing fetal harm. Advise females of reproductive age of the potential risk to a fetus and to use appropriate contraception.
Documentation & Availability
What documents are required to import CYRAMZA to India?
CYRAMZA (ramucirumab) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation are needed to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is CYRAMZA available in India?
CYRAMZA (ramucirumab injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability of Cyramza in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
CYRAMZA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of CYRAMZA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com for Cyramza price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the CYRAMZA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Cyramza®?
Ramucirumab is Generic Name for the trade name drug Cyramza®.
What is the Manufacturer Name of Cyramza®?
Cyramza® is manufactured by the Eli Lilly and Company.
Is Cyramza® approved by the FDA?
Yes, Cyramza® is approved by the FDA. Date of approval: April 21, 2014.
Is Cyramza® a Vesicant?
No, Cyramza is not a vesicant.
What kind of drug is Ramucirumab?
Ramucirumab is in a class of drugs known as monoclonal antibodies.
Is Cyramza® an immunotherapy?
Yes, Cyramza is an immunotherapy drug. It acts in order to target and restrict a protein that helps stimulate blood vessel growth within tumors.
What is the dosage and form of Cyramza® supplied?
Cyramza® is supplied as Injection: 100 mg/10 mL (10 mg/mL) or 500 mg/50 mL (10 mg/mL) solution in a single-dose vial for intravenous administration.
What are the side effects due to Cyramza®?
Some side effects due to Cyramza may occur during the injection. Tell your health specialist right away if you feel chilled, light-headed, sweaty, or have chest pain, chest tightness, trouble breathing, back pain, or numbness and tingling. Cyramza® can increase the probability of serious bleeding.
How much does Cyramza® cost in India?
The Cyramza cost in India is reasonable and can vary. In order to procure this VEGFR2 antagonist authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Cyramza®?
Store the vials of Cyramza in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from the light until time of use. Neither freeze nor shake the vials.
What are the Highlights of prescribing information for Cyramza®?
Click Here to download full Cyramza Prescribing Information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
